Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research.

Smith EE, Phillips NA, Feldman HH, Borrie M, Ganesh A, Henri-Bhargava A, Desmarais P, Frank A, Badhwar A, Barlow L, Bartha R, Best S, Bethell J, Bhangu J, Black SE, Bocti C, Bronskill SE, Burhan AM, Calon F, Camicioli R, Campbell B, Collins DL, Dadar M, DeMarco ML, Ducharme S, Duchesne S, Einstein G, Fisk JD, Gawryluk JR, Grossman L, Ismail Z, Itzhak I, Joshi M, Harrison A, Kröger E, Kumar S, Laforce R, Lanctot KL, Lau M, Lee L, Masellis M, Massoud F, Mitchell SB, Montero-Odasso M, Myers Barnett K, Nygaard HB, Pasternak SH, Peters J, Rajah MN, Robillard JM, Rockwood K, Rosa-Neto P, Seitz DP, Soucy JP, Trenaman SC, Wellington CL, Zadem A, Chertkow H, Canadian Consortium on Neurodegeneration in Aging Investigators

Open source

DOI: 10.1016/j.tjpad.2025.100068
Published: 2025 Mar
Container: The journal of prevention of Alzheimer's disease
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.tjpad.2025.100068,
  title = {Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research.},
  author = {Smith EE and Phillips NA and Feldman HH and Borrie M and Ganesh A and Henri-Bhargava A and Desmarais P and Frank A and Badhwar A and Barlow L and Bartha R and Best S and Bethell J and Bhangu J and Black SE and Bocti C and Bronskill SE and Burhan AM and Calon F and Camicioli R and Campbell B and Collins DL and Dadar M and DeMarco ML and Ducharme S and Duchesne S and Einstein G and Fisk JD and Gawryluk JR and Grossman L and Ismail Z and Itzhak I and Joshi M and Harrison A and Kröger E and Kumar S and Laforce R and Lanctot KL and Lau M and Lee L and Masellis M and Massoud F and Mitchell SB and Montero-Odasso M and Myers Barnett K and Nygaard HB and Pasternak SH and Peters J and Rajah MN and Robillard JM and Rockwood K and Rosa-Neto P and Seitz DP and Soucy JP and Trenaman SC and Wellington CL and Zadem A and Chertkow H and Canadian Consortium on Neurodegeneration in Aging Investigators},
  year = {2025},
  journal = {The journal of prevention of Alzheimer's disease},
  doi = {10.1016/j.tjpad.2025.100068},
  url = {https://doi.org/10.1016/j.tjpad.2025.100068}
}

RIS

TY  - JOUR
TI  - Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research.
AU  - Smith EE
AU  - Phillips NA
AU  - Feldman HH
AU  - Borrie M
AU  - Ganesh A
AU  - Henri-Bhargava A
AU  - Desmarais P
AU  - Frank A
AU  - Badhwar A
AU  - Barlow L
AU  - Bartha R
AU  - Best S
AU  - Bethell J
AU  - Bhangu J
AU  - Black SE
AU  - Bocti C
AU  - Bronskill SE
AU  - Burhan AM
AU  - Calon F
AU  - Camicioli R
AU  - Campbell B
AU  - Collins DL
AU  - Dadar M
AU  - DeMarco ML
AU  - Ducharme S
AU  - Duchesne S
AU  - Einstein G
AU  - Fisk JD
AU  - Gawryluk JR
AU  - Grossman L
AU  - Ismail Z
AU  - Itzhak I
AU  - Joshi M
AU  - Harrison A
AU  - Kröger E
AU  - Kumar S
AU  - Laforce R
AU  - Lanctot KL
AU  - Lau M
AU  - Lee L
AU  - Masellis M
AU  - Massoud F
AU  - Mitchell SB
AU  - Montero-Odasso M
AU  - Myers Barnett K
AU  - Nygaard HB
AU  - Pasternak SH
AU  - Peters J
AU  - Rajah MN
AU  - Robillard JM
AU  - Rockwood K
AU  - Rosa-Neto P
AU  - Seitz DP
AU  - Soucy JP
AU  - Trenaman SC
AU  - Wellington CL
AU  - Zadem A
AU  - Chertkow H
AU  - Canadian Consortium on Neurodegeneration in Aging Investigators
PY  - 2025
JO  - The journal of prevention of Alzheimer's disease
DO  - 10.1016/j.tjpad.2025.100068
UR  - https://doi.org/10.1016/j.tjpad.2025.100068
ER  -

APA

EE, S., NA, P., HH, F., M, B., A, G., A, H., P, D., A, F., A, B., L, B., R, B., S, B., J, B., J, B., SE, B., C, B., SE, B., AM, B., F, C., R, C., B, C., DL, C., M, D., ML, D., S, D., S, D., G, E., JD, F., JR, G., L, G., Z, I., I, I., M, J., A, H., E, K., S, K., R, L., KL, L., M, L., L, L., M, M., F, M., SB, M., M, M., K, M. B., HB, N., SH, P., J, P., MN, R., JM, R., K, R., P, R., DP, S., JP, S., SC, T., CL, W., A, Z., H, C., & Investigators, C. C. O. N. I. A. (2025). Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research.. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2025.100068

Source records

pubmed · retrieved 2026-09-26T18:02:59.752Z